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ARTICLE
A de novo microdeletion of SEMA5A in a boy with
autism spectrum disorder and intellectual disability
Anne-Laure Mosca-Boidron*,1,2,15, Lucie Gueneau2,15, Guillaume Huguet3,4,5, Alice Goldenberg6, Céline Henry7,
Nadège Gigot2, Emilie Pallesi-Pocachard8, Antonio Falace8, Laurence Duplomb2, Julien Thevenon2,9,
Yannis Duffourd2, Judith ST-Onge2,10, Pascal Chambon6, Jean-Baptiste Rivière2,10, Christel Thauvin-Robinet2,9,
Patrick Callier1,2, Nathalie Marle1,2, Muriel Payet1,2, Clemence Ragon1,2, Hany Goubran Botros3,4,5,
Julien Buratti3,4,5,11, Sophie Calderari3,4,5,11, Guillaume Dumas3,4,5, Richard Delorme3,4,5,12, Nathalie Lagarde7,
Jean-Michel Pinoit7, Antoine Rosier13, Alice Masurel-Paulet9, Carlos Cardoso8, Francine Mugneret1,
Pascale Saugier-Veber14, Dominique Campion14, Laurence Faivre2,9,15 and Thomas Bourgeron3,4,5,11,15
Semaphorins are a large family of secreted and membrane-associated proteins necessary for wiring of the brain. Semaphorin 5A
(SEMA5A) acts as a bifunctional guidance cue, exerting both attractive and inhibitory effects on developing axons. Previous
studies have suggested that SEMA5A could be a susceptibility gene for autism spectrum disorders (ASDs). We ﬁrst identiﬁed a
de novo translocation t(5;22)(p15.3;q11.21) in a patient with ASD and intellectual disability (ID). At the translocation
breakpoint on chromosome 5, we observed a 861-kb deletion encompassing the end of the SEMA5A gene. We delineated the
breakpoint by NGS and observed that no gene was disrupted on chromosome 22. We then used Sanger sequencing to search for
deleterious variants affecting SEMA5A in 142 patients with ASD. We also identiﬁed two independent heterozygous variants
located in a conserved functional domain of the protein. Both variants were maternally inherited and predicted as deleterious.
Our genetic screens identiﬁed the ﬁrst case of a de novo SEMA5A microdeletion in a patient with ASD and ID. Although our
study alone cannot formally associate SEMA5A with susceptibility to ASD, it provides additional evidence that Semaphorin
dysfunction could lead to ASD and ID. Further studies on Semaphorins are warranted to better understand the role of this family
of genes in susceptibility to neurodevelopmental disorders.
European Journal of Human Genetics (2016) 24, 838–843; doi:10.1038/ejhg.2015.211; published online 23 September 2015
INTRODUCTION
Autism spectrum disorders (ASDs) are characterized by impairments
in social interactions, stereotypy and a restricted repertoire of activity
and interest. ASDs affect 0.6–1.5% of the population, with 4–8 times
more males diagnosed than females.1,2 ASDs are etiologically hetero-
geneous and are associated with an identiﬁed genetic etiology in about
20% of cases.3–5 ASD can be associated with known genetic disorders
such as fragile X syndrome, tuberous sclerosis (TSC1, TSC2),
neuroﬁbromatosis (NF1), Angelman syndrome (UBE3A), Rett syn-
drome (MECP2), and Cowden syndrome (PTEN). Microscopically
visible chromosomal alterations and copy-number variations (CNVs)
account for 3–10% of cases.6 Finally, de novo disruptive variants are
more frequent in patients with ASD than in their unaffected siblings
and controls.7–11 The role of inherited variants remains unclear, but it
was estimated that at least 6% of cases could be caused by rare
recessive variants affecting both alleles and that common variants
act in an additive manner to increase the genetic risk to autism.12–14
Based on current ﬁndings, the genetic architecture of ASD is highly
heterogeneous, with many genes/loci and possibly gene–gene interac-
tions involved.4,5
Genes associated with ASD participate in at least three main
biological processes.4,5,15 The ﬁrst pathway is related to chromatin
remodeling and includes genes such as MECP2 (mutated in patients
with Rett syndrome) and CHD8. The second pathway is related to the
PI3K-mTOR signaling pathway and includes variants in NF1, TSC1,
TSC2, and PTEN that normally inhibit translation.16 Downstream of
the PI3K-mTOR signaling pathway, proteins directly involved in the
inhibition of mRNA translation at the synapse (FMR1, CYFIP1,
EIF4E) are also mutated in ASD.17 The third pathway concerns the
balance between excitation and inhibition and the formation and
maintenance of synapses.5,18 At the synapse, cell adhesion proteins
such as neuroligins and neurexins and scaffold proteins such as
SHANK3 are involved in dendrite formation and the assembly of
synapses.19 In addition, epilepsy-associated voltage-gated sodium
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channels such as SCN1A were also found mutated in patients with
ASD. Finally, guidance cues for axonal outgrowth such as semaphorins
were also associated with ASD suggesting that abnormal wiring of the
brain could be a risk factor for ASD.18 The semaphorin SEMA5A gene
was associated with ASD according to independent results from
(i) genome-wide association studies (GWAS)20,21 and expression
assay,22 (ii) RNA proﬁling of brains20 and B lymphoblastoid cell
lines22 from patients with ASD, and (iii) pathway analysis using
expression quantitative traits loci (eQTL) and CNV data.23 SEMA5A is
also one of the genes deleted in the minimal region in patients
presenting with ‘cri-du chat’ syndrome and a subset of these patients
present autistic traits including repetitive movements, obsessive
attachment to objects, hypersensitivity to sensory stimuli, gaze
avoidance, and social isolation.24
Semaphorins are a large and diverse family of secreted and
membrane-associated proteins, which are conserved both structurally
and functionally across divergent animal phyla25,26 (Figure 1a). All
members of this family contain a conserved extracellular domain of
about 500 amino acids, termed the semaphorin domain, which is
characterized by highly conserved cysteine residues that have been
found to form intrasubunit disulﬁde bonds (Figure 1b). Class 5
semaphorins (SEMA5A and SEMA5B) are characterized by the
presence of seven type 1 thrombospondin repeats in their extracellular
domain. Both SEMA5A and SEMA5B seem to play a crucial role in the
development of neuronal circuits.27–30 Using a rat model, Kantor
et al.29 found that SEMA5A acts as a bifunctional guidance cue,
exerting both attractive and inhibitory effects on developing axons of
the fasciculus retroﬂexus, a diencephalon ﬁber tract associated with
limbic function. More recently, Duan et al.28 showed that SEMA5A
negatively regulates synaptogenesis in early, developmentally born,
hippocampus. SEMA5A is strongly expressed by the hippocampal
dentate granule cells and regulates dendritic spine density in a cell-
autonomous manner.28 Mice lacking SEMA5A display deﬁcits in social
interaction, a hallmark of ASD.28
Here, we report the ﬁrst case of a de novo translocation t(5;22)
(p15.3;q11.21) associated with a partial deletion of SEMA5A in a
patient with ASD. In order to determine the contribution of SEMA5A
to ASD, we then ascertained the clinical characterization of this patient
and screened for SEMA5A variants.
MATERIALS AND METHODS
Cohorts of patients with ASD
To identify SEMA5A coding variants, we sequenced a cohort of 142 patients
(121 males) from three different French genetic centers (Paris, Rouen, and
Dijon). Affected individuals were diagnosed using the Autism Diagnostic
Interview-Revised (ADI-R)31 and/or the Autism Diagnostic Observation
Schedule (ADOS) according to DSM-IV and ICD-10 criteria. Standard
karyotype, fragile X testing, and metabolic screening for inherited metabolism
disorders (plasma and urinary amino acids, urinary mucopolysaccharides and
organic acids, urinary purines and pyrimidines, urinary creatinine, and
guanidoacetate) showed no abnormalities. There were no speciﬁc inclusion
criteria for the screening for SEMA5A coding variants. The cohort of 142
patients consisted of 87% of individuals with autism, 10% of individuals with
atypical autism (including PDD-NOS), and 3% of individuals with Asperger
syndrome. The cohort of CNVs consisted of 996 cases and 1287 controls from
the Autism Genome Project, and 296 patients and 509 controls from our
laboratory. In accordance with ethical guidelines, written informed consent was
collected from all patients or from their parents or guardians, and from all the
other participating careers before inclusion in the study. The approval of
the ethics committee of Dijon University Hospital was not required since the
analyses were performed as part of the diagnostic work-up and did not require
additional samples. The parents or guardians of the patients signed an informed
consent form for publication of the data.
Standard and molecular cytogenetic studies
After clinical examination by a geneticist, the chromosomes of the proband and
his parents were obtained from peripheral blood lymphocyte cultures using
standard cytogenetic analysis with R and G banding techniques. Whole-
chromosome painting analysis of chromosomes 5 and 22 was performed in
the proband. CNVs were detected using the Human Genome Microarray CGH
44K, from Agilent according to the manufacturer’s protocol (Agilent Tech-
nologies, Santa Clara, CA, USA) and different Illumina SNP arrays (Human
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Figure 1 Semaphorin phylogeny and structure. (a) Primary structures of the semaphorin family in mammals. (b) Structure of the SEMA5A protein and
locations of the coding variants (c.2026C4T, c.2852C4G, c.2866A4G, c.2983C4T). The microdeletion identiﬁed in this study is indicated in red and the
star represents the de novo missense variant (c.2852C4G) reported by Lossifov et al.35 The conservation of the amino acids is indicated for different
species. TM, transmembrane domain; TSP, thrombospondin repeat.
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Omni 1, Omni 2.5, and Omni 5 BeadChip arrays). CGH data were processed
with Feature Extraction (v. 9.1) software and the results were analyzed with
CGH analytics (v. 4.0) software (Agilent). Mapping data were analyzed on the
human genome sequence using Ensembl (www.ensembl.org; Hg 19). CNVs
were assessed in the Database of Genomic Variants (http://projects.tcag.ca/
variation/). CNV identiﬁed by microarray analyses was conﬁrmed by ﬂuores-
cence in situ hybridization (FISH) using BACs RP11-747E07 and RP11-57N07
(The Human 32 K clone set, CHORI) on metaphase chromosome preparations
and by quantitative PCR targeting the SEMA5A gene in the proband and in his
parents. Real-time PCR was performed in the LightCycler 480 system (Roche)
using the SYBR Green I Master Kit (Eurogentec, Seraing, Belgium) with 2 μl of
cDNA and 200 nM of each primer. Each reaction was performed in triplicate.
Sequencing of SEMA5A
Genomic DNA was extracted from EDTA-blood by the salting-out method.
PCR ampliﬁcation of all 21 SEMA5A coding exons and exon–intron boundaries
was performed using the Taq DNA polymerase from Invitrogen. All PCR
products were directly sequenced using an ABI Genetic Analyser 3100 capillary
sequencer according to the manufacturer’s instructions (Applied Biosystems,
Foster City, CA, USA). The reference sequence of SEMA5A genomic DNA was
downloaded using Ensembl Genome Browser (accession number
ENSG00000112902). Nomenclature for the description of sequence variants
was based on the current Ensembl transcript (Ensembl Transcript ID
ENST00000382496) with the position +1 as the A of the ATG initiation
codon. Collected data were analyzed with SeqScape v2.7 software (Applied
Biosystems).
Next-generation sequencing of the translocation breakpoints
Breakpoint detection was based on whole-genome sequencing with the paired-
end protocol and speciﬁc bioinformatics analysis (Integragen, Evry, France).
Library preparation, sequencing, and variant detection and annotation were
performed by IntegraGen. The generated paired-end libraries were prepared
according to the Agilent Technologies process. For detailed explanations of this
process, please see SureSelect XT2 Target Enrichment System for Illumina
Multiplexed Sequencing Protocol (version B, April 2012). Note that only the
pre-capture step was processed to generate paired-end libraries and the shearing
process was modiﬁed to yield long DNA fragments. Brieﬂy, 1 μg of genomic
DNA was fragmented by sonication and puriﬁed. The mode of the resulting
fragment-size distribution was approximately 400 bp. Indexed paired-end
adaptor oligonucleotides were ligated on repaired A-tailed fragments, then
puriﬁed and enriched by four PCR cycles to increase the yield. Each DNA
library was quantiﬁed by qPCR using speciﬁc Illumina oligonucleotides and
then sequenced on an Illumina HiSeq 2000, where genomic paired-end reads of
2× 100 nucleotides were generated. Image analysis and base calling were
performed using Illumina Real Time Analysis Pipeline version 1.14 with default
parameters.
The bioinformatics analysis of sequencing data was based on BWA for the
alignment step, and on GASV software for breakpoint detection. Reads
alignment was performed with multiseed and gapped alignments on reference
human genome hg19 and reads were paired with a median fragment size of
300 bp. Sequences with more than two mismatches were excluded, as were
duplicated sequences corresponding to PCR ampliﬁcation bias. Then, from the
alignment, a list of reads mapped to different chromosomes for translocations
was retained. Finally, only abnormalities supported by three independent pairs
of reads were veriﬁed. If this analysis scheme was not sufﬁcient to identify the
breakpoints, six mismatches per sequence were tolerated.
RESULTS
We analyzed the contribution of SEMA5A variants in ASD using a
panel of genetic technologies including standard karyotyping and SNP
arrays, as well as Sanger and next-generation sequencing. We report
for the ﬁrst time on a 4-year-old-boy with ASD carrying a de novo
translocation leading to a partial deletion of SEMA5A on chromosome
5. He was referred to the Genetics Department because of psycho-
motor delay associated with abnormal behavior. The pregnancy was
uneventful and he was born at 36 weeks and 5 days of gestation by
caesarean section because of a breech presentation. The birth
measurements were as follows: weight: 2.4 kg, length: 43 cm, and
occipitofrontal circumference (OFC): 33 cm. He had suffered from
asthma since the ﬁrst month of his life. He was the third of three
siblings and his two brothers had speech delay that was rapidly
corrected and did not require any further investigation. At 4 years of
age the physical examination revealed normal growth parameters
(weight: 17 kg, height: 100 cm, and OFC 51.5 cm) and there were no
discernible dysmorphic features. In particular, he presented no
features of ‘cri-du chat’ syndrome such as microcephaly, hypertelor-
ism, and hypotonia. He had no visceral malformation, a normal
cardiac, and renal ultrasound. Brain MRI was reported as normal. His
reciprocal interactions and communication skills were impaired. He
showed evidence of the ﬁrst symptoms of ASD at 18 months of age as
he did not react to noise (hearing was tested and appeared normal),
and at 2 years he presented with speech delay. At the age of 4 years he
could only pronounce sounds. The history of his early development
was difﬁcult to assemble. The diagnosis of childhood autism was ruled
out according to the Autism Diagnosis Interview-Revised because of
the absence of restricted and stereotyped patterns of interest.31 He met
the ICD-10 criteria for PDD—not otherwise speciﬁed as he had
severely impaired verbal and non-verbal communication, and
impaired social interactions. Moreover, at 5 years of age, the results
of the Psychoeducational Proﬁle-Revised (PEP-R) indicated a
developmental score equivalent to an age of 17 months and conﬁrmed
the associated diagnosis of intellectual disability (ID).
The karyotype analysis of the patient and his parents revealed a
de novo translocation 46,XY, t(5;22)(p15.3;q11.2) (Figure 2a).
Whole-chromosome painting analysis of chromosomes 5 and 22
showed that the chromosomal rearrangement involved only these
two chromosomes (data not shown). To determine whether there
were any losses or gains of material around the breakpoints of the
translocation, we performed SNP/CNV analysis using the Illumina
2.5M array (Figure 2b). At the translocation breakpoint on chromo-
some 5, we observed an 861-kb deletion in the 5p15.3 region
(arr[hg19] 5p15.3(8,205612–9,066,802)× 1 dn). The deletion was
conﬁrmed by FISH and qPCR and was de novo since it was only
observed in the proband and not in the parents. Next-generation
sequencing deﬁned the breakpoint in a 361-bp region on chromosome
5 at 5p15.3 (chr5:g.90685589_9068950, hg19) and on chromosome 22
in a repetitive element at 22q11.21 (chr22:g.18718082_18718443,
hg19). No gene was disrupted on chromosome 22. We therefore
conﬁrmed that the patient was carrying a de novo partial deletion of
the SEMA5A gene (exons 17–23). The deletion has been submitted to
Decipher (patient ID 280507, URL: https://decipher.sanger.ac.uk/).
The Database of Genomic Variants reported only one intragenic
deletion (nsv597070).
In order to detect additional SEMA5A variants in patients with
ASD, we sequenced all coding exons of the gene in 142 independent
patients. We found one nonsynonymous variant (c.2866A4G
p.(Ser956Gly) NM_003966.2) already listed in dbSNP and two
nonsynonymous variants (c.2026C4T p.(Arg676Cys) and c.2983C4T
p.(Arg995Trp) NM_003966.2). The ﬁrst one has never been reported
in the ExAC and in the Exome Variant Server (EVS) databases, but a
neighboring variant c.2027G4A p.(Arg676His) has been reported in
the ExAC database at a very low frequency (MAF= 0.00001666). The
second one was present in the ExAC database in a similar very low
frequency (MAF= 0.00001666). Both variants c.2026C4T and
c.2983C4T were located in highly conserved regions of the throm-
bospondin and the transmembrane domains, respectively, and have
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been submitted to LOVD (patients IDs 00037526 and 00037568),
URL: www.lovd.nl/SEMA5A (Figure 1b). These variants were mater-
nally inherited and predicted as deleterious by Polyphen2 and SIFT
algorithms. Based on the EVS, rare SEMA5A variants are found in
0.56% of individuals from European ancestors (ASD: 2/142 vs EVS
controls 24/4300; Fisher's exact test, two-tailed: P= 0.2). Based on the
recent screen for de novo variants in ASD, a de novo missense variant
of SEMA5A (c.2852C4G p.(Ser951Cys)) affecting a conserved amino
acid and predicted as deleterious was identiﬁed in a female with ASD.
In our study, the patient carrying the c.2026C4T variant is a
6-year-old boy, the second child of non-consanguineous parents. The
family history revealed a schizophrenic paternal uncle. The pregnancy
was normal and he was born at 37 weeks of gestation. Birth weight
was 2870 g (3rd centile) and OFC was at the 95th centile (36.5 cm). He
showed evidence of the ﬁrst symptoms of ASD at 20 months of age as
he had psychomotor delay and abnormal behavior. He had no visceral
malformation, in particular a normal cardiac and renal ultrasound.
Brain MRI was reported as normal. He walked between 16 and
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Figure 2 Characterization of the chromosomal rearrangement leading to the microdeletion of the SEMA5A gene. (a) Partial G-banded karyotype showing the
translocation t(5;22)(p15.3;q11.21) of the proband. (b) Results of the SNP-array (Illumina Human Omni 2.5) analysis showing the de novo 861-kb deletion
(chr5:8205612-9068974 hg19) of the region 5p15.3 including the seven last exons of SEMA5A. Based on informative SNPs located within the deletion, we
ascertained that the deletion was on the father’s chromosome. Each dot shows logR ratio (LRR; in red), the B allele frequency (BAF; in green), and the copy
number (CN; in blue).
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18 months of age and said his ﬁrst words between 8 and 12 months of
age. At the age of 1 year he stopped talking and showed impaired
social reciprocity, slightly aggressive behavior, and stereotyped hand
movements. He was referred to a psychiatric unit at 4 years of age
because of deﬁcits in verbal communication associated with repetitive
behaviors and was diagnosed with autism, according to DSM-IV and
ICD-10 criteria. The severity of the autistic behavior was assessed
using the Childhood Autism Rating Scale scores. The score of 41.5
corresponded to moderate to severe ASD and, despite his psychomo-
tor delay, he did not present ID. When examined at 6 years of age, he
was 116 cm tall (50th centile), weighed 21 kg (50th centile), and had
an OFC of 56 cm (497th centile); the neurological examination was
normal. Presence of a variant of the PTEN gene and other pathogenic
CNVs was excluded by Sanger sequencing and 105 K CGH-array,
respectively. He presented mild dysmorphism including hypertelorism
and a wide mouth. He used non-verbal communication and had
aggressive behavior.
The patient carrying the maternally inherited c.2983C4T variant is
a 6-year-old boy, the second child of non-consanguineous parents.
The family history was uneventful, except for the mother who
experienced two episodes of depression, one at 11 years of age and
the second at age 36. Her psychiatric evaluation showed good
reciprocal social interactions. The pregnancy was marked by maternal
hepatic steatosis and the proband was born at 37.5 weeks of gestation.
Birth weight was 2760 g (3rd centile), length 49 cm (50th centile), and
an OFC of 31.5 cm (o3rd centile). Apgar scores were 4 and 9 at 1 and
5min, respectively. At 1 month of age he presented with hypotonia,
motor agitation, and no babbling. He walked at 18 months and he
could only say two words at 2 years. He had no visceral malformation,
in particular a normal cardiac and renal ultrasound. Brain MRI was
reported as normal. He was referred to a psychiatric unit because of
aggressive behavior and speech delay. He was diagnosed with ASD,
according to DSM-IV and ICD-10 criteria. He met the criteria for
autism according to ADI-R and ADOS. His cognitive level was in the
normal range. When examined at 6 years of age he was 122 cm tall
(97th centile), weighed 25 kg (97th centile), and had an OFC of 50 cm
(50–25th centile). The neurological examination was normal and no
pathogenic CNVs were detected by the 105 K array-CGH.
DISCUSSION
In the literature, multiple lines of evidence support a role for SEMA5A
in susceptibility to ASD. First, a large-scale GWAS performed on 1031
independent families with ASD initially found a statistically genome-
wide signiﬁcant association between ASD and rs10513025 located 5′ to
SEMA5A.20 Following this GWAS, an association between the same
SNP and ASD was also detected using the transmission disequilibrium
test in 227 Italian families with ASD.21 Another common SNP of
SEMA5A (rs42352) was associated with hippocampal volume and
memory performance in 329 healthy Chinese adults.32 Second, in a
recent GWAS follow-up approach analyzing SNPs that affect gene
expression (eQTL), Cheng et al.23 found that the SEMA5A regulatory
network signiﬁcantly overlaps with rare autism-speciﬁc CNVs. The
SEMA5A regulatory network includes previous ASD candidate genes
and regions including MACROD2, CDH8, FOXP1, AUTS2, MBD5,
among others.23 Third, two independent studies have reported a
reduced level of SEMA5A mRNA in Epstein–Barr virus-transformed B
lymphocytes22 or in the brains of patients with ASD.20 Finally,
SEMA5A is located on chromosome 5 in a minimal region deleted
in patients with ‘cri-du chat’ syndrome. A subset of these patients
presents with autistic traits including repetitive movements, obsessive
attachment to objects, hypersensitivity to sensory stimuli, gaze
avoidance, and social isolation.24
While these studies suggest that SEMA5A plays a role in suscept-
ibility to ASD, none of them could formally implicate SEMA5A. In
this study, we report the ﬁrst microdeletion of SEMA5A caused by an
unbalanced reciprocal translocation in a patient with ASD and severe
speech delay. The deletion (exons 17–23) found in the boy with ASD
caused the loss of seven exons coding the last ﬁve thrombospondin
repeats, as well as the transmembrane and the intra-cytoplasmic
domains. SEMA5A CNVs are very rare events since they were not
detected in the large cohort of ASD patients screened by Pinto et al.6
Our mutation screening also identiﬁed two patients with ASD carrying
private missense variants located in highly conserved regions of
SEMA5A and predicted to alter protein function. Remarkably, the
c.2026C4T p.(Arg676Cys) variant alters an arginine residue that is
highly conserved in many thrombospondin domains outside the
semaphorin family suggesting that this amino acid is important for
correct protein folding. The thrombospondin repeats of SEMA5A
were shown to be crucial to promote axon outgrowth through the
interaction with proteins such as PlexinA2, but the exact mapping of
the protein–protein interaction remains unknown.28,29,33
To conclude, our study reports the ﬁrst de novo microdeletion of
SEMA5A in humans. The phenotype of the patient might be consistent
with a role of SEMA5A in patients with ASD and ID without
dysmorphic features. Together with the recent results from the
whole-exome sequencing in ASD, this variation is the second de novo
SEMA5A variation reported in ASD.34,35 As for other inherited rare
variants identiﬁed in complex disorders, we cannot formally prove
that the two missense variants identiﬁed in this study represent risk
factors for ASD. These variants affected highly conserved amino acids,
but were inherited from asymptomatic mothers, thus signifying that if
they do play a role in ASD, they might be only one of the factors
contributing to the disorder. Indeed, a combination of rare inherited
variants was reported in a subset of patients, suggesting a ‘multiple hit’
model of ASD.36,37 Altogether, the role of SEMA5A variants in ASD
seems limited and very large-scale studies are warranted to associate
this gene to ASD, but given the importance of semaphorins in the
wiring of the brain, any information on the clinical consequences of
deleterious variants affecting this family of proteins remains very
helpful to understand the numerous neurobiological mechanisms
leading to neurodevelopmental disorders.
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